Attenuated psychosis syndrome: Need for debate on a new disorder

Psychopathology

Volumn 47, Issue 5, 2014, Pages 287-291

  Carpenter, William T ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Early intervention; Prevention; Prodrome; Psychosis; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMAN; PRESCRIPTION; PSYCHOLOGY; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; STANDARDS; SYNDROME; UNNECESSARY PROCEDURE;

ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG PRESCRIPTIONS; HUMANS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; SYNDROME; UNNECESSARY PROCEDURES;

EID: 84908659076     PISSN: 02544962     EISSN: 1423033X     Source Type: Journal    
DOI: 10.1159/000365221     Document Type: Article

References (14)

1. McGlashan TH, Walsh BC, Woods SW: The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up. Oxford, Oxford University Press, 2010.
2. Yung AR, Woods SW, Ruhrmann S, Addington J, Schultze-Lutter F, Cornblatt BA, Amminger GP, Bechdolf A, Birchwood M, Borgwardt S, Cannon TD, de Haan L, French P, Fusar-Poli P, Keshavan M, Klosterkötter J, Kwon JS, McGorry PD, McGuire P, Mizuno M, Morrison AP, Riecher-Rössler A, Salokangas RKR, Seidman LJ, Suzuki M, Valmaggia L, van der Gaag M, Wood SJ, McGlashan TH: Whither the attenuated psychosis syndrome? Schizophr Bull 2012; 38: 1130-1134.
3. Tsuang MT, Van Os J, Tandon R, Barch DM, Bustillo J, Gaebel W, Gur RE, Heckers S, et al: Attenuated psychosis syndrome in DSM-5. Schizophr Res 2013; 150: 31-35.
4. Heckers S: Who is at risk for a psychotic disorder? Schizophr Bull 2009; 35: 847-850.
5. Carpenter WT: Anticipating DSM-V: should psychosis risk become a diagnostic class? Schizophr Bull 2009; 35: 841-843.
6. Fusar-Poli P, Carpenter WT, Woods SW, McGlashan TH: Attenuated psychosis syndrome: ready for DSM-5.1? Annu Rev Clin Psychol 2014; 10: 155-192.
7. Carpenter WT, van Os J: Should attenuated psychosis syndrome be a DSM-V diagnosis? Am J Psychiatry 2011; 168: 460-463.
8. Regier DA, Narrow WE, Clarke DE, Kraemer HC, Kuramoto SJ, et al: DSM-5 field trials in the United States and Canada. Part II: Testretest reliability of selected categorical diagnoses. Am J Psychiatry 2013; 170: 59-70.
9. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP, Kendall T: Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013; 346:f185.
10. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler R, et al: The psychosis high-risk state: a comprehensive stateof-the-art review. JAMA Psychiatry 2013; 70: 107-120.
11. Strauss JS, Carpenter WT: Schizophrenia. New York, Plenum Press, 1981.
12. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ: Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust NZ J Psychiatry 2006; 40: 616-622.
13. McGorry PD: Early clinical phenotypes, clinical staging and strategic biomarker research: building blocks for personalized psychiatry. Biol Psychiatry 2013; 74: 394-395.
14. Amminger P, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE: Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomised, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-154.